Investigator

Ying Jing

PI · Greater Bay Area Institute of Precision Medicine, Center for Intelligent Medicine

Research Interests

YJYing Jing
Papers(3)
Distinct immune cell …Radiotherapy‐Associat…Single‐Nucleus Transc…
Collaborators(2)
Jianming TangJian Song
Institutions(3)
Fudan UniversityLanzhou UniversityJiangxi Provincial Ac…

Papers

Single‐Nucleus Transcriptome Profiling of Locally Advanced Cervical Squamous Cell Cancer Identifies Neural‐Like Progenitor Program Associated with the Efficacy of Radiotherapy

AbstractRadiotherapy is the first‐line treatment for locally advanced cervical squamous cell cancer (CSCC). However, ≈50% of patients fail to respond to therapy and, in some cases, tumors progress after radical radiotherapy. Here, single‐nucleus RNA‐seq is performed to construct high‐resolution molecular landscapes of various cell types in CSCC before and during radiotherapy, to better understand radiotherapy related molecular responses within tumor microenvironment. The results show that expression levels of a neural‐like progenitor (NRP) program in tumor cells are significantly higher after radiotherapy and these are enriched in the tumors of nonresponding patients. The enrichment of the NRP program in malignant cells from the tumors of nonresponders in an independent cohort analyzed by bulk RNA‐seq is validated. In addition, an analysis of The Cancer Genome Atlas dataset shows that NRP expression is associated with poor prognosis in CSCC patients. In vitro experiments on the CSCC cell line demonstrate that downregulation of neuregulin 1 (NRG1), a key gene from NRP program, is associated with decreased cell growth and increased sensitivity to radiation. Immunohistochemistry staining in cohort 3 validated key genes, NRG1 and immediate early response 3 from immunomodulatory program, as radiosensitivity regulators. The findings reveal that the expression of NRP in CSCC can be used to predict the efficacy of radiotherapy.

26Works
3Papers
2Collaborators
Tumor MicroenvironmentCarcinoma, Squamous CellNeoplasm Recurrence, LocalCarcinoma, Non-Small-Cell LungImmune System DiseasesLung NeoplasmsBone Neoplasms

Positions

2023–

PI

Greater Bay Area Institute of Precision Medicine · Center for Intelligent Medicine

2021–

PI

Shanghai Jiao Tong University School of Medicine · Clinical Research Institute

2018–

Postdoc fellow

The University of Texas Health Science Center at Houston · Department of Biochemistry and Molecular Biology

2014–

Research Associate

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital · Clinical stem cell research center

Education

2014

Ph.D

Fudan University

Keywords
immune related adverse eventscancer immunotherapy